Search companies

Live

Tuesday, 17 November 2026 · 577 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

TrivarX Advances Stabl-Im Toward First Human Study, Targets Enrolment Next Year

TrivarX Limited (TRI) · Health care

TRI: $0.009 +12.50% · MC: $12M

TrivarX says it has progressed preparations for Stabl-Im’s planned Phase 1 healthy-volunteer study, including starting pre-clinical work, receiving investigational product and appointing Syntro Health after quarter-end to prepare and test trial supplies. First participant enrolment is targeted for early 2027, with initial study results anticipated later that year, subject to remaining requirements; pre-clinical results are expected in the current quarter. The company reported approximately A$2 million in cash at quarter-end.

Source announcements: 2026-10-30 08:56 to 2026-10-30 08:56 Sydney time
Story updated 2026-10-30 08:59 Sydney time
SourcesSeptember 2026 Quarterly Activities Report and Appendix 4C
Comments